by Dr. C.H. Weaver M.D. 2/2021
About Libtayo (cemiplimab-rwlc)
Libtayo is a fully human monoclonal antibody precision medicine know as a “checkpoint inhibitor”. Libtayo targets the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo block cancer cells from using the PD-1 pathway to suppress T-cell activation.
In a phase III clinical trial called EMPOWER-Lung 1 Libtayo was compared to platinum-doublet chemotherapy in patients with squamous or non-squamous advanced NSCLC that tested positive for PD-L1 in ≥50% of tumor cells, but not for ALK, EGFR or ROS1. The PD-1 inhibitor Libtayo® (cemiplimab) when compared to platinum-doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression in tumor cells extends overall survival and reduces the risk of death by 43% among those with confirmed PD-L1 expression of 50% or higher.
Libtayo is no yet FDA approved in the United States but undergoing review. When approved it will represent the 5th PD-1 checkpoint inhibitor approved for the treatment of NSCLC.
- Keep Current With The CancerConnect NSCLC Community Newsletter
- Connect With Others In The CancerConnect NSCLC Community To Share Information And Support
Can KRAS Positive Colorectal and Lung Cancer Finally be Targeted?
New precision medicines effectively target KRAS mutations in lung, colon, and other cancers.